The First Anniversary of "Langmu" Listing - Lighting the Road of Chinese Biopharmaceutical Innovation June 18, 2015 Source: Yingzhong Media From May 24th to 28th, the first anniversary of the listing of Compaqer (trade name “Langmuâ€) was set off from Xi'an. In less than a week, it has covered seven major cities including Beijing, Guangzhou, Chengdu and Shenyang. Everywhere there is a sensation in the ophthalmology world. The tour was not only supported by many top domestic experts such as Wang Ningli, Yao Ke, Yan Jia, Li Xiaoxin, Xu Xun, Lin Xiaofeng, Zhao Mingwei, Wei Wenbin, etc., but also invited two international-level fundus diseases "big names" - Boston Ophthalmology Professor Jeffrey Heier of the Counseling Center and Professor Peter.K. Kaiser of the Cole Eye Institute of the Cleveland Clinic. As a new generation of 100% humanized recombinant fusion protein, Compaqep can act on VEGF-A, VEGF-B and PlGF simultaneously compared to the monoclonal antibody that only acts on VEGF-A single target in the market. An important target, the use of Compaqip in the treatment of wet AMD, not only significantly improve the patient's vision, but also reduce the frequency of injection, further improve the safety, greatly reduce the cost of drug treatment, improve patient compliance. Professor Peter.K. Kaiser presented management experience in patients with wet age-related macular degeneration through extensive clinical studies and meta-analysis of safety data in his lecture presentation. He believes that the security problems that may arise from Fc fragments and VEGF-B are very one-sided and wrong interpretations of some articles, and some evidences are also wrongly derived. Overall, a large number of head-to-head studies, including CATT, IVAN, VIBERA, and LUCAS, have confirmed that anti-VEGF drugs are safe. Studies such as VIEW1, VIEW2, and PHOENIX have shown that fusion protein drugs can reduce the number of injections and reduce the incidence of complications on the basis of ensuring efficacy and subsequent efficacy. Compaqip is an independent research and development of Chengdu Kanghong Biotechnology Co., Ltd., with the independent intellectual property rights of "China created" Class I biological new drugs, is the national "11th Five-Year" major new drug creation" special results, it is the first in China to obtain WHO's international generic name for new biopharmaceuticals. Although the time to market was just one year, Compaqerp represented the Chinese independent innovation national brand new drugs in the international and domestic major top ophthalmology conferences, which caused a sensation at home and abroad. At the same time, Kanghong Pharmaceutical and Bethune Fund Management The committee set up the "Bethune Langmu Young and Young Ophthalmology Research Fund" to support the clinical research work of young and middle-aged ophthalmologists; and jointly launched the "Langshijie Muguangming" public welfare fund with the China Social Relief Fund to provide assistance to patients with poor fundus macular degeneration. activity. In addition, it also organized a charity event to "care for the war veterans" to provide medical assistance and veteran support for veterans. The focus and appeal at both academic and public welfare not only received the full support of experts in the ophthalmology industry, but also its public welfare behavior has been widely recognized in the industry. The experience of the year has enabled Kang Hongren to firmly believe that Compaq Xipu will enter the global market in the near future and become internationalized, becoming the shining star of China's heavy innovative drugs. Universal A.I. Sheaths With Green Insert Universal A.I. Sheaths,Custom Universal A.I. Sheath,Pe Insert Split Sheaths,New Universal Ai Plug-In Sheath Jinan Mucho Commercial Inc. , https://www.muchovet.com